{"name":"Insignis Therapeutics, Inc.","slug":"insignis-therapeutics-inc","ticker":"","exchange":"","domain":"insignis.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQcGlWZXJJblI0Yi1HQTRvdHp5WGpINzZSSUVwNkIxN2RKVEVZczV6N1lkNzBrM0NINFg2bWNqVWdOLWxuT3laWlRxV3NKTUZ4d04zU2RnMlhCbm1SclYtdE5jTlA0ZUFUWFFmLWdzaXdaaHZ0cGJkZVd4emxDbHNCMlJZaU9oX2VRMHN1RFRpX3dQaHVyZGxFRFlhWDRlb1RFLTl4S1RJSlFRSkNrOUxQWUw4eDhfUFp6N2RiMw?oc=5","date":"2026-03-11","type":"pipeline","source":"seekingalpha.com","summary":"ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - seekingalpha.com","headline":"ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQQTJucFVSWllZVXlmRWFrUE15MjVWXzFlQjN6bnM2dy02bmFoenJVQXZLYmlpemRIbGlBSFJRYU5NOEVqaWYzZlVUT0NrUm94NV83NHVydFF0bERLeFRfeTRXUlFHLWlVWWp1YUlJeVVCcGRyTk9tVkJnOC1ZenZ4WUM4N1FwWjhhYVI3SXNvaUt4QXdnREw5R3Q0T0thTFFmVlRIY3Z1blR6WnI3ZFhudWx0Tk1ONDAxRXJhTA?oc=5","date":"2025-11-10","type":"earnings","source":"seekingalpha.com","summary":"ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating (SPRY) - seekingalpha.com","headline":"ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating (SPRY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOR1FodGg0Zk84VmlualBXV0lFa05kTjJtUnhiV1F2LVhUTHd3aWdTX1d2NXM5aTRzU0otY0pmOU15WWFkZlNZVl82YVR1ZEdmZ0tjZ1psbW9iTFk5eW50TzlzVzBvaFhNM05YTFhxT2FxRHFvSFZuTjcwRU8wNFdNd0NTN3QwWDVZY0dEekZuTWdRbVpVcVJ2emlHN09ZQ3MyOGpzZVo4Yk8wQVdrOV9MMGFPbWNCQQ?oc=5","date":"2025-07-10","type":"pipeline","source":"seekingalpha.com","summary":"ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY) - seekingalpha.com","headline":"ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPdnhFZGhmOG95S0tvMTZMdU9wcFU4RzBsUGwwM2FvLWtPYWJOZUdJOVlqd3p0UHVxRWJTdzVsblp0aWdjNVQ2M20wM0d0N2hJa1lkS25tam9ESnVuU1dJc3B4ckh5WUpOZ000cFJLLWJQak16ZGxlOGQxcFFvLVN1S2tfYlEtOXV3ckJXakk3ZVZYZ2ZUc2xLbVJiX2tHaHptSU10VEpDLTdhbXRRRE5WWkJn?oc=5","date":"2025-03-20","type":"earnings","source":"seekingalpha.com","summary":"ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await (NASDAQ:SPRY) - seekingalpha.com","headline":"ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await (NASDAQ:SPRY)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}